Industry News
Discovery Of A Genetic Cause Of Glioblastoma May Lead To New Treatment
Jul 29, 2012
Researchers at Columbia University Medical Center (CUMC) have discovered that some cases of glioblastoma, the most common and aggressive form of primary brain cancer, are caused by the fusion of two adjacent genes. The study also found that drugs that target the protein produced by this genetic aberration can dramatically slow the growth of glioblastomas in mice... Read More
Discovery Of A Genetic Cause Of Glioblastoma May Lead To New Treatment
Jul 29, 2012
Researchers at Columbia University Medical Center (CUMC) have discovered that some cases of glioblastoma, the most common and aggressive form of primary brain cancer, are caused by the fusion of two adjacent genes. The study also found that drugs that target the protein produced by this genetic aberration can dramatically slow the growth of glioblastomas in mice... Read More
Protein Discovery Links To Cancer Research
Jul 28, 2012
A Simon Fraser University graduate student's collaboration with her thesis supervisor on how a particular type of protein controls the growth of another protein could advance cancer research. Their findings have just been published in the online issue of Current Biology, a CellPress journal... Read More
Protein Discovery Links To Cancer Research
Jul 28, 2012
A Simon Fraser University graduate student's collaboration with her thesis supervisor on how a particular type of protein controls the growth of another protein could advance cancer research. Their findings have just been published in the online issue of Current Biology, a CellPress journal... Read More
Malignant Melanoma Drug Trabedersen Receives Orphan Designation From FDA
Jul 27, 2012
TGF-β2 inhibitor has gained market exclusivity in the USA for a third aggressive cancer indication The biopharmaceutical company Antisense Pharma GmbH announces that the US Food and Drug Administration (FDA) has granted Orphan Drug designation for its investigational oncology antisense compound trabedersen to treat malignant melanoma... Read More
Malignant Melanoma Drug Trabedersen Receives Orphan Designation From FDA
Jul 27, 2012
TGF-β2 inhibitor has gained market exclusivity in the USA for a third aggressive cancer indication The biopharmaceutical company Antisense Pharma GmbH announces that the US Food and Drug Administration (FDA) has granted Orphan Drug designation for its investigational oncology antisense compound trabedersen to treat malignant melanoma... Read More
Risk For Basal Cell Carcinoma Can Be Chronic
Jul 27, 2012
In the powerful sunlight of July, newly published results from a large study of people at high risk for basal cell carcinoma support the emerging view of the nation's most common cancer as a chronic ailment that often repeatedly afflicts older people but for which the seeds may be planted in youth. The research also found a new association with eczema... Read More
Center Researchers Shed Light On New Multiple Myeloma Therapy
Jul 27, 2012
Researchers from John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, played leading roles in three separate multi-center studies with the new proteasome inhibitor carfilzomib published in Blood, a major peer-reviewed scientific journal... Read More
Center Researchers Shed Light On New Multiple Myeloma Therapy
Jul 27, 2012
Researchers from John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, played leading roles in three separate multi-center studies with the new proteasome inhibitor carfilzomib published in Blood, a major peer-reviewed scientific journal... Read More
Fluid Flow And Tumor Invasion
Jul 27, 2012
There are many factors that affect tumor invasion, the process where a tumor grows beyond the tissue where it first developed. While factors like genetics, tissue type and environmental exposure affect tumor metastasis and invasion, physical forces like fluid flow remain a poorly understood component of tumor invasion... Read More
Previous Page Next Page